Publish Your Article


Coronavirus – AstraZeneca antibodies approved for infection prevention in US

Evusheld reduces the risk of infection by 77%, but is not intended for widespread use

Green light from the US Food and Drug Administration (FDA) AstraZeneca antibody cocktail to prevent Covid-19 in people with a weakened immune system or a history of serious side effects from a coronavirus vaccine.

The Evusheld antibody cocktail was approved only for adolescents and adults who have not been ill and have not recently come in contact with a case, the agency said.

According to Reuters, the approval of Evusheld, which contains the antibodies tixagevimab and cilgavimab, is a significant development for the British-Swedish AstraZeneca, whose vaccine has not yet been approved in the US.

Clinical trials have shown that Evusheld reduces the risk of Covid-19 symptoms by 77%. Preventive treatment includes two injections and offers protection for several months to a year.

The US has already ordered 700,000 installments.

However, the FDA has made it clear that Evushed is not a substitute for the vaccine for people who are recommended to be vaccinated.

AstraZeneca synthetic monoclonal antibodies work much like the natural antibodies offered by the vaccine and are designed to stay in the blood for months to block the virus in case of infection.

Similar treatments have been developed by other pharmaceutical companies such as Regeneron, Eli Lilly and GlaxoSmithKline.

Source: tanea

Related posts

Blood-curdling image: He broke his leg to escape from the soldier


Zelensky: "Russia's recognition of these fake referendums will mean that there is nothing left to discuss with this Russian president"


LIVETEXT War in Ukraine, day 217 | Zaporozhye power plant, targeted by new attacks. Explosions near reactors


Hurricane Ian nightmare in America: Thousands flee

Leave a Reply

Your email address will not be published.